depressive disorder

Jatrorrhizine (neprotin) is a protoberberine alkaloid isolated from Enantia chlorantha (Annonaceae) and other species. It was found to have antimicrobial and antifungal activity. It binds and noncompetitively inhibits monoamine oxidase (IC50 4 micromolar for MAO-A and 62 for MAO-B).

Jatrorrhizine chloride (Neprotine chloride) is a potent and orally active uptake-2 transporter inhibitor. It exhibits a critical neuroprotective role in H2O2-induced apoptosis via inhibition of the MAPK pathway in HT22 hippocampal neurons.

GW791343 trihydrochloride (GW791343 3HCl) is aHCl salt form of GW791343, which is a non-competitive allosteric modulator of human P2X7 receptor inhibitor with pIC50 of 7.

GW791343 dihydrochloride (GW791343 (HCl)) is a P2X7 allosteric modulator.

Vilazodone (SB659746A) is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system.

Imiloxan (RS-21361) is an α2 adrenergic receptor antagonist used in the treatment of major depressive disorder.

Liafensine(BMS-820836) is a novel and selective triple monoamine reuptake inhibitor with inhibitory effects on the reuptake of serotonin, norepinephrine, and dopamine for the study of major depressive disorder and central nervous system disorders.

Zalospirone is a 5-HT1A receptor agonist that can be used to study anxiety disorders and major depressive disorder.

Agomelatine (Valdoxan) is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression.

Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a thiophene derivative and selective neurotransmitter uptake inhibitor for serotonin and noradrenaline (SNRI). It is an antidepressant agent and anxiolytic, also used for treating pain in patients with diabetes mellitus and fibromyalgia.

Venlafaxine (Wy 45030), an arylalkanolamine serotonin-norepinephrine reuptake inhibitor (SNRI), is used to treat major generalised anxiety disorder (GAD), depressive disorder (MDD), panic disorder and social phobia.

Vilazodone Hydrochloride (EMD 68843) , a partial agonist of 5-HT1A receptors and specific serotonin reuptake inhibitor (SSRI), is utilized in treating of the major depressive disorder.

ZZL-7 is a fast-onset antidepressant agent that disrupts the interaction between neuronal nitric oxide synthase (nNOS) and the serotonin transporter (SERT) in the dorsal raphe nucleus (DRN). It easily crosses the blood-brain barrier and has research value in major depressive disorder (MDD).

CGP 25454A is a selective antagonist that acts on presynaptic dopamine autoreceptors; CGP 25454A promotes increased release of dopamine and acetylcholine and has potential applications in research on major depressive disorder.

Duloxetine-D3 hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for the treatment of major depressive disorder and generalized anxiety disorder (GAD). Duloxetine D3 hydrochloride ( (S)-Duloxetine D3 hydrochloride) is a deuterium-labeled Duloxetine hydrochloride (TMSM-3429).

Brilaroxazine (RP5063) is a potent multimodal dopamine/5-HT modulator. Brilaroxazine is a partial agonist of dopamine D2, D3, and D4 receptors, 5-HT1A (Ki =1.5 nM) and 5-HT2A (Ki = 2.5 nM), and has antagonist activity 5-HT2B, and 5-HT7 receptors with Kis of 0.19 nM and 2.7 nM, respectively. Brilaroxazine can be used for research about cognitive impairments in neuropsychiatric and neurological diseases.

LY2940094 (LY-2940094) decreases ethanol self-administration in animal models. LY2940094 is an effective, selective, and orally available nociceptin receptor antagonist with high affinity (Ki=0.105 nM) and antagonist potency (Kb=0.166 nM).

Orvepitant maleate is an effective, selective, and well-tolerated neurokinin-1 receptor (NK-1) antagonist (pKi: 10.2 for human neurokinin-1 receptor). Orvepitant maleate has the potential for depressive disorder and chronic refractory cough (CRC) treatmen

Gepirone is a selective 5-HT1A agonist that selectively binds to 5-HT1A receptor sites. It is employed as an antidepressant in research studies focused on anxiety and major depressive disorder.

Clomipramine (Clomicalm) is a tricyclic antidepressant (TCA). It is used for the treatment of the panic disorder, obsessive-compulsive disorder, major depressive disorder, and chronic pain. It may decrease the risk of suicide in those over the age of 65. It is similar to Imipramine in that selective inhibition of the serotonin uptake in the brain.

Forvisirvat (SP-624) is an orally active, brain-permeable, and selective activator of the silent information regulator protein 6 (SIRT6). It enhances the deacetylase activity of SIRT6, promotes DNA repair and mitochondrial health, and demonstrates antidepressant effects in animal models. Forvisirvat holds promise for the investigation of major depressive disorder.

Fumiporexant (Compound Example 93) is an orally active, brain-penetrant, and selective antagonist of orexin receptor 2 (OX2R). It regulates the sleep-wake cycle and pathways related to mood in the central nervous system. Fumiporexant holds potential for research into neurological disorders such as insomnia and major depressive disorder.

DLX48 is a transporter inhibitor that binds to the active site of the LeuBAT (Δ13 mutant) transporter. It can traverse the blood-brain barrier and presents a low risk of drug interactions related to cytochrome P450. DLX48 is applicable in research on major depressive disorder.

Trazodone (AF-1161), a 5-HT 2A/2C receptor antagonist, is used as an antidepressant for treating major anxiety disorders and depressive disorder.